Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial

By sjmartinez • November 14, 2024

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Ansari W, Harrington MA, Simón-Campos A, Chew KW, Pypstra R, Rusnak JM. Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial. Clin Infect Dis. 2024 Nov 11:ciae551. doi: 10.1093/cid/ciae551. Epub ahead of print. PMID: 39523543.

Tags: COVID-19 drug therapy, EPIC-HR, Infectious Diseases, nirmatrelvir, Publications, ritonavir, Symptoms

Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden[...]

Community-Based Adaptation and Evaluation of a Peer-Led Intervention to Address Alcohol Use and HIV in Pregnant and Breastfeeding Women in South Africa: Protocol for the “Mentor Mothers Plus” Randomized Control Trial

Essack Z, Petersen Z, Miller AP, Schoetz Dean S, Daniels D, Hofmeester H, Belin T, van Rooyen H, Louw J, Joseph Davey D. Community-Based Adaptation[...]

Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections

Singh S, Youssef EG, Barbarino A, Hautau H, Nabeela S, Gebremariam T, Alkhazraji S, Ostroff G, Christensen D, Cochrane T, Ibrahim AS. Next-generation Candida albicans[...]